Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.34 |
| ▸ | PDE4A | P27815 | 6/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ATF4 | P18848 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240837 | 0.74 | ALDH1A1 (0.31) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13126846 | 0.70 | PDE4D (0.34) | PDE4D | |
| SCHEMBL7803266 | 0.69 | PDE4D (0.33) | PDE4D | |
| SCHEMBL22602147 | 0.69 | PDE4D (0.33) | PDE4D | |
| SCHEMBL12708160 | 0.69 | PDE4D (0.33) | PDE4D | |
| SCHEMBL13617237 | 0.69 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6840506 | 0.69 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL938041 | 0.69 | ATF4 (0.34) | PDE4DPDE4APDE4BPDE4CATF4 | |
| SCHEMBL13563616 | 0.68 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15327797 | 0.68 | CTSL (0.35) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | PDE4D 4338/4885PDE4A 3409/4885PDE4B 3607/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | PDE4D 4338/4885PDE4A 3409/4885PDE4B 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.